Chosa Oncology AB (CHOSA.ST)
Stockholm · SEK · Healthcare · Biotechnology
SEK 0.544 (-1.81%) as of
Key statistics
- Market cap
- 49.74M
- EPS (TTM)
- -0.0700
- Dividend yield
- 0.00%
- 52-week range
- 0.4090 – 1.9900
- Beta
- -0.01
- Profit margin
- 0.00%
- Volume
- 41.99k
About Chosa Oncology AB
Chosa Oncology AB, together with its subsidiaries, engages in developing and commercializing medicines for the treatment of cancer in Sweden and USA. It provides Platin-DRP, a multigene mRNA-based algorithm that predicts a patient's response to platinum-based chemotherapy; and LiPlaCis, a liposomal formulation of cisplatin, enabling delivery of chemotherapy agent directly to tumor sites. The company was formerly known as Chosa ApS. Chosa Oncology AB was incorporated in 2015 and is based in Malmö, Sweden.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Malmö, Sweden
- Employees
- 2
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.